Introduction
During the last years, the mammalian target of rapamycin (mTOR) inhibitors, such as everolimus and sirolimus, were frequently used as potent immunosuppressants in renal and cardiac transplant therapy due to the lack of nephrotoxicity as well as potential antitumor effects [1] [2] [3] . Nevertheless, while several clinical renal transplant studies have suggested the beneficial effects of calcineurin inhibitor-free, mTOR inhibitor-based protocols, unexpected adverse effects of mTOR inhibitors have also been described during treatment of renal allograft nephropathy [4] [5] [6] , human glomerulonephritis [7] , as well as experimental kidney disease [8, 9] . The mTOR inhibitors are potent antiproliferative agents for lymphocytes, and also for other cell types such as vascular smooth muscle cells [1] , endothelial cells [10] and mesangial cells [11] . Everolimus is a lipophilic macrocyclic lactone bind- ing to the FK-binding protein 12, while this complex then inhibits mTOR and thereby arrests the cell cycle in the transition of G1 to S phase. These antiproliferative effects are considered to be especially beneficial for hyperproliferative lesions such as cardiac transplant vasculopathy, vascular restenosis after balloon dilatation or, theoretically, in mesangial proliferative glomerulonephritides such as IgA nephropathy. In contrast, we recently demonstrated the detrimental effects of everolimus therapy in an experimental rat model of acute mesangial proliferative glomerulonephritis, the anti-Thy1 model, in which everolimus treatment unexpectedly transformed this acute reversible model into a chronic disease model with sclerosis in more than 30% of the glomeruli [8] . While this acute reversible anti-Thy1 model perfectly demonstrates the successful healing reaction of severely injured glomeruli with involvement of both the glomerular endothelium and the mesangium, the situation of human mesangial proliferative glomerulonephritis may be better matched by the chronic anti-Thy1 model. This model is induced after uninephrectomy with antibody 1-22-3 [12] [13] [14] , and has a very similar time course during the first 2 weeks to the acute anti-Thy1 model. Here, early mesangial injury with severe mesangiolysis and glomerular endothelial injury, with the frequent formation of glomerular microaneurysms, are followed by a coordinated repair reaction by mesangial and endothelial migration and proliferation. The glomerular architecture is substantially restored 2 weeks after disease induction and characterized by hypercellular lesions with increased matrix expansion. While in the acute anti-Thy1 model glomeruli return to an almost completely normal structure during the next few months, the time course of the chronic anti-Thy1 model after the first 2 weeks is characterized by progressive proteinuria, matrix accumulation, tubulointerstitial lesions and focal segmental glomerulosclerosis (FSGS)-like lesions similar to human FSGS. Considering the evidence from the acute anti-Thy1 model [8] , where early treatment was most detrimental, we examined whether a late start of everolimus therapy at the end of the acute proliferative phase may even lead to beneficial effects in the chronic anti-Thy1 model.
Methods

Animal Model and Experimental Design
The animal studies were performed in accordance with the internal animal review board (Regierung von Mittelfranken: 621-2531.31-17/05). Male Sprague-Dawley rats (Charles River, Sulzfeld, Germany) weighing 105-145 g were used for this study. The animals were fed standard rat chow (Altromin 1324, Spezialfutterwerke GmbH, Lage, Germany) and tap water ad libitum.
Seven days after uninephrectomy, experimental chronic mesangial proliferative glomerulonephritis (chronic anti-Thy1 model) was induced by an injection of the monoclonal anti-Thy1 antibody 1-22-3 (0.5 mg/100 g body weight) [12] [13] [14] ( fig. 1 ). To evaluate the best starting point for everolimus therapy, 3 rats each were investigated in a pilot experiment before and on days 7 and 14 after induction of chronic anti-Thy1 nephritis. At the beginning of treatment on day 14 the animals were randomized after measuring proteinuria into 2 groups. Microemulsion formulations (Self-micro-emulsifying-drug-delivery system) of vehicle and everolimus for oral administration were provided by Novartis Pharmaceuticals, Inc. (Basel, Switzerland) and were diluted in phosphate-buffered saline. Vehicle or everolimus were given once daily orally via gavage at a dose of 2.5 mg/kg body weight. This dose resulted in trough levels of 7.6 8 2.25 ng/ml as determined by tandem mass spectrometry, which was consistent with other studies [15] . Since the adverse effects of everolimus treatment have been described during the acute phase of the anti-Thy1 model, everolimus treatment was started 14 days after induction of the chronic anti-Thy1 disease model. At that chosen time point, the typical mesangial and endothelial lesions as indicated by mesangiolysis and microaneurysm formation were almost completely repaired via cellular proliferation and migration ( fig. 2 ). All rats were randomly allocated to two different groups with chronic mesangial proliferative nephritis (n = 10), one vehicle-and one everolimus-treated ( fig. 1 ) . A serum sample and 24-hour urine collection for measuring proteinuria and serum creatinine were done at periodic intervals. After 8 weeks the systolic blood pressure was recorded using the tail-cuff plethysmographic method. The rats were sacrificed after 17 weeks (119 days) and the tissue samples were processed and stored as needed.
Renal Morphology and Immunohistochemistry
Tissue for light microscopy was fixed in methyl Carnoy's solution, embedded in paraffin, and cut into 2-m sections for periodic acid Schiff reagent (PAS) or indirect immunoperoxidase staining as described elsewhere [16, 17] . The following antibodies were used in this study: PC10, a murine IgG1 monoclonal antibody (mAb) against the human proliferating cell nuclear antigen (PCNA), cross-reactive with rat (DAKO, Glostrup, Denmark) [16, 17] ; ED-1, a murine monoclonal IgG1 mAb to a rat cytoplasmic antigen present in monocytes, macrophages, and dendritic cells (Linaris, Wertheim-Bettingen, Germany) [16, 17] ; sc-152, a rabbit polyclonal antibody to human vascular endothelial growth factor (VEGF)-A cross-reactive with rat VEGF (Santa Cruz Biotechnology, Santa Cruz, Calif., USA) [18] ; JG12, a murine IgG mAb specific for rat aminopeptidase P on endothelial cells (Bender MedSystems GmbH, Vienna, Austria) [19, 20] ; sc-8418, a murine monoclonal antibody against rat p70S6 kinase (Santa Cruz Biotechnology) [21] ; sc-8416, a murine monoclonal antibody to phosphorylated p70S6 kinase recommended for detection in rats (Santa Cruz Biotechnology) [21] ; a rabbit polyclonal antibody against rat fibronectin (FN; Chemicon, Temecula, Calif., USA) [22] ; a murine monoclonal antibody for human desmin (DAKO, Glostrup, Denmark); a murine IgG mAb against the Thy1 epitope specific for rat mesangial cells (clone Ox-7; Serotec Ltd, Oxford, UK) [23] , and monocyte chemotactic protein-1 (MCP-1), a goat polyclonal antibody against a peptide mapping at the C-terminus of MCP-1 of the rat (sc-1785; Santa Cruz Biotechnology).
Negative controls for immunostaining included either deleting the primary antibody or substitution of the primary antibody with equivalent concentrations of an irrelevant murine mAb or pre-immune rabbit IgG. For each biopsy, 30-60 glomerular cross-sections (400-to 600-fold magnification) or 20 visual fields (200-fold magnification) were evaluated in a blinded fashion. Glomerular expression of VEGF was graded semiquantitatively and reflected changes in the area and intensity of mesangial staining. Glomerular expression of FN, VEGF and MCP-1 was quantified by a semiquantitative scoring system (0 = 0%, 1 = ! 25%, 2 = ! 50%, 3 = ! 75%, 4 = 1 75%). In the case of immunostaining for desmin, only the podocytes on the outer edge of the glomerular tuft were assessed as described elsewhere [24] . A semiquantitative staining score from 0 to 4 was used to represent the percentage ranges of the outer edge showing positive staining (0 = 0%, 1 = 1-25%, 2 = 26-50%, 3 = 51-75%, 4 = 76-100%). The lack of immunostaining of either the endothelium (JG12) or the mesangium (Ox-7) was evaluated by a semiquantitative scoring system from 0 to 4 (0 = normal capillary/ mesangial structure, 1 = ! 25%, 2 = ! 50%, 3 = ! 75%, 4 = 1 75% loss of endothelium/mesangium) reflecting glomerular capillary rarefaction or mesangiolysis. The glomerular cell number was counted in the immunostaining of phosphorylated p70S6 kinase. Glomerular hypertrophy was evaluated by computerized measurement of the glomerular area using the MetaVue Imaging System (Visitron Systems GmbH, Puchheim, Germany). It has been shown previously that this semiquantitative scoring system is reproducible between different observers and that the data obtained correlate with those obtained by computerized morphometry [18, 25] .
Isolation of Glomeruli
This method was performed in a cold storage room (4 ° C). After withdrawal of the kidney the renal cortex was minced with a razor blade, pressed using a pusher through a sieve with a mesh size of 106 m 2 and rinsed with phosphate-buffered saline. Larger contaminations were retained on a second sieve with a mesh size of 180 m 2 and glomeruli were collected on a third sieve with a mesh size of 75 m 2 . Small contaminations washed through all sieves. The collected glomeruli were transferred to a sterile blue cap and concentrated by centrifugation at 1,000 rpm for 5 min.
The glomeruli were lysed in RLT buffer for RNA isolation (Qiagen RNeasy Mini Kit).
Quantification of Glomerular TGF-␤ 1, VEGF, PAI-1 and FN by Real-Time PCR
RNA isolation (Qiagen RNeasy Mini Kit) and reverse transcription (Abgene, UK) were performed according to the manufacturer's instructions. The cDNA of transforming growth factor-␤ 1 (TGF-␤ 1), VEGF, plasminogen activator inhibitor-1 (PAI-1) and FN was amplified and quantified by real-time PCR (ABI Prism 7000, Applied Biosystems), using the Taqman/SYBR (Abgene, UK) assay reagent methods and the comparative threshold cycle method. TGF-␤ 1, VEGF, PAI-1 and FN mRNA expression was normalized to ␤ -actin mRNA. For this PCR, 3 l of each cDNA sample was mixed with 17 l Taqman/SYBR Master Mix, which includes the 2 ! Taqman/SYBR solution, target primers, RNAse-free water, and the equal probe for the Taqman method. The final concentration for the forward and reverse primers in the Taqman reaction was 900 n M and for the probe 250 n M . By contrast, in the SYBR the reaction was used at a final concentration for both primers of 100 n M . The results were reproducible.
The following rat-specific PCR-primers were used in this study. 
Miscellaneous Measurements
Urinary protein was measured using the BioRad Protein Assay (BioRad, Munich, Germany) and BSA (Pierce, Bonn, Germany) as standard in concentrations from 10 to 500 g/ml according to the manufacture's instructions.
Statistical Analysis
The Kolmogorov-Smirnov test was used to test normality. The result showed that there was no normal distribution in all the parameters analyzed. So the statistical significance was evaluated using the Mann-Whitney test. The outcomes are displayed as box plots or dot plots. The box plots and dot plots were drawn in SPSS. A box plot is a convenient way of graphically depicting the 5-number summary. The box represents 50% of all events, whereby the line in the box shows the median. The 'whiskers' (vertical bars) e49 extend to at most 1.5 times the box length. They must end at an observed value, thus connecting all the values outside the box that are not more than 1.5 times the box length away from the box. Three times the box length marks the boundary between 'mild' and 'extreme' outliers (shown as dots). All values in this text are expressed as mean 8 SD.
Results
Everolimus Treatment Was Started at a Time when the Glomerular Architecture Was Almost Restored
Since adverse effects of everolimus treatment have been described during the acute phase of the anti-Thy1 model, everolimus treatment was started 14 days after disease induction of the chronic anti-Thy1 model. At that chosen time point, the typical mesangial and endothelial lesions, as indicated by mesangiolysis and microaneurysm formation, were almost completely repaired via cellular proliferation and migration, as shown in a representative aminopeptidase P staining on endothelial cells (JG12; fig. 2 A) and Ox-7 staining for the mesangium ( fig. 2 C) . Semiquantitative scoring of glomerular capillary rarefaction from 0 to 4 revealed quite prominent endothelial damage on day 7 after model induction, reaching values of 2.0 8 0.22. Fourteen days after nephritis induction, the appearance of microaneurysms was very rare and glomerular capillary rarefaction declined to a score of 0.8 8 0.28, indicating nearly complete reconstitution of the endothelium ( fig. 2 B) . In parallel, mesangiolysis was reduced from a score 1.1 8 0.21 on day 7 to nearly complete mesangial restoration on day 14 (score 0.6 8 0.14), as measured by Ox-7 positivity of the glomeruli ( fig. 2 D) . At earlier time points (days 1-2), mesangiolysis scores up to 3.5-4 can be observed [8] . Indirect damage of podocytes, as quantified by immunostaining against desmin, was relatively low and not different on days 7 and 14 after induction of chronic anti-Thy1 nephritis ( fig. 2 E) . On day 7, glomerular proliferative activ- ity was six times higher than in healthy rats, but returned to normal values on day 14 after disease induction, as shown by staining for PCNA, indicating that repair by proliferative activity was completed ( fig. 2 F) .
Everolimus Prevents FSGS Lesions in Chronic Anti-Thy1 Nephritis
A typical end point in chronic mesangioproliferative nephritis is the formation of FSGS lesions as defined by scarred segmental injury of the glomerulus that includes synechia between the tuft and Bowman's capsule ( fig. 3 A) . Sixteen weeks after model induction, everolimus treatment reduced the formation of FSGS lesions by 35% compared to animals treated with vehicle ( fig. 3 B) . Damage of podocytes, as analyzed by immunostaining against desmin, was increased twofold (not significant, p = 0.2) in vehicle-treated animals (score 1.2 8 0.8) compared to the evaluation on days 7 (score 0.6 8 0.1) and 14 (score 0.6 8 0.1; fig. 2 E) . In contrast, everolimus treatment resulted in podocyte damage (score 0.68 8 0.68) equivalent to early time points of chronic anti-Thy1 nephritis on days 7 and 14 ( fig. 2 E) . Tubulointerstitial fibrosis was relatively low, as shown in figure 3 C, and was almost significantly reduced (p = 0.05) by everolimus therapy ( fig. 3 D) . 
Everolimus Reduces Glomerular Deposition and Expression of FN in Chronic Anti-Thy1 Nephritis
Glomerular FN, a matrix protein, was significantly decreased by 30 8 9% in the everolimus-treated group as shown by the semiquantitative scoring system ( fig. 4 A) . In addition, glomerular FN mRNA was significantly downregulated by 50 8 8% in the everolimus-treated group ( fig. 4 B) . The most important pro-fibrotic cytokine in renal disease is TGF-␤ . To investigate the potential influence of everolimus on the TGF-␤ signal transduction system we analyzed TGF-␤ 1 mRNA expression, the TGF-␤ signal transduction molecule Smad 2/3 and the TGF-␤ downstream target PAI-1. Neither expression of TGF-␤ 1 itself ( fig. 4 C) , nor phosphorylation of the TGF-␤ signal transduction molecule Smad 2/3 ( fig. 4 D) , nor expression of PAI-1 ( fig. 4 E) was affected by everolimus therapy.
Everolimus Inhibits VEGF and Phosphorylation of the p70S6 Kinase during Chronic Anti-Thy1 Nephritis
Everolimus binds to FK-binding protein 12 and this complex inhibits mTOR, which affects the phosphorylation of p70S6 kinase. Expression of glomerular p70S6 kinase, as analyzed by immunostaining, was not influenced by everolimus ( fig. 5 A) . In contrast, phosphorylation of . * Significant changes at p ! 0.05. E The glomerular endothelium was analyzed by a capillary rarefaction score using JG12 immunostaining and was not affected long-term. e52 p70S6 kinase was significantly reduced by 26 8 5.5% in everolimus-treated rats compared to placebo-treated animals ( fig. 5 B) .
To investigate the long-term impact of everolimus on the glomerular endothelium, we investigated glomerular capillary rarefaction and the regulation of the important pro-angiogenic factor VEGF. Everolimus therapy significantly reduced glomerular VEGF immunostaining by 22 8 4% as indicated by semiquantitative scoring ( fig. 5 C) . In addition, renal glomerular VEGF mRNA was significantly decreased by more than 50% in everolimus-treated animals compared to the vehicle-treated group as assessed via real-time PCR ( fig. 5 D) . Despite these inhibitory effects on VEGF, glomerular capillary rarefaction as assessed by scoring of JG12 staining was not significantly affected by long-term everolimus treatment ( fig. 5 E) .
Everolimus Inhibits Hypertrophy and Inflammation in Chronic Anti-Thy1 Nephritis
During chronic anti-Thy1 nephritis, the glomerular area increased by 20 8 6% in vehicle-treated animals compared to age-matched healthy rats (about 7,000 m 2 as revealed by another of our studies, data not published; fig. 6 A) . Everolimus therapy prevented enlargement of the glomerular cross-sectional area ( fig. 6 A) . Since glomerular cell number was not different in everolimus-and vehicle-treated rats, glomerular enlargement does not appear to be due to increased cell numbers ( fig. 6 B) , but cellular hypertrophy does. Nevertheless, since everolimus is known for its antiproliferative effects, we also examined proliferative activity at the end of the study. In both groups only a low number of PCNA-positive cells was seen and 'low grade proliferation' was significantly re- e54 duced in the everolimus-treated compared to vehicletreated rats ( fig. 6 C) .
Inflammatory cells are important mediators of fibrosis induction, therefore influx of macrophages was investigated by immunohistochemistry. Influx of monocytes/ macrophages, as demonstrated by the number of ED1-positive cells, was significantly decreased by more than 50% by everolimus treatment in both the glomerular and interstitial compartment ( fig. 6 D, E) . Since the influx of monocytes/macrophages was decreased by mTOR inhibition, we also examined the chemokine MCP-1 by immunostaining, which was not different in the diseased glomeruli of everolimus-versus placebo-treated rats ( fig. 6 F) .
Everolimus Prevents Proteinuria in Chronic Anti-Thy1 Nephritis
Proteinuria was analyzed as a marker of severity of nephropathy. At the beginning of treatment (on day 14), the animals were randomized to either the everolimus-or vehicle-treated group. Proteinuria increased with time after induction of chronic anti-Thy1 nephritis in the vehicle-treated group ( fig. 7 A) . This increase in proteinuria was prevented by everolimus therapy ( fig. 7 A) . The ⌬ -proteinuria showing the difference in proteinuria between the start and the end point of therapy was very small in the everolimus-treated group and significantly lower compared to vehicle-treated animals ( fig. 7 B) . The beneficial effects of everolimus were not due to effects on blood pressure, since blood pressure was similar in both groups ( fig. 7 C) . Renal function was not affected by everolimus therapy ( fig. 7 D) .
Discussion
Unexpected adverse effects of mTOR inhibitors, such as the induction of proteinuria and renal deterioration [5, 29, 30] , have been described. In this context, we recently demonstrated the severe adverse effects of everolimus therapy in acute experimental mesangial proliferative glomerulonephritis in the rat (reversible anti-Thy1 model) [8] , where inhibition of capillary repair by everolimus in the especially vulnerable mesangiolytic phase and acute proliferative phase with the occurrence of microaneurysms seemed to be most critical. This acute reversible anti-Thy1 model can be converted into a chronic mesangial proliferative glomerulonephritis model by uninephrectomy and the use of the anti-Thy1 antibody 1-22-3 [12] [13] [14] . Hereby, the first mesangiolytic and hyperproliferative phase is basically identical to the reversible anti-Thy1 model, but instead of a complete healing reaction, glomerular hypertrophy, hypercellularity and matrix expansion slowly progress over the next few months. We hypothesized that treatment with everolimus starting after the acute proliferative phase with a largely intact glomerular capillary convolute could even be beneficial in the chronic anti-Thy1 model.
Confirming our hypothesis, our major finding of this study is that everolimus therapy initiated 14 days after disease induction (at a time when glomerular endothelium and mesangium was restored) did not worsen the time course of experimental chronic mesangial proliferative glomerulonephritis, although the same drug doses were used as in the reversible anti-Thy1 model [8] leading to clinically relevant drug levels (6-10 ng/ml). Rather, everolimus caused beneficial long-term effects after 4 months of therapy as indicated by inhibition of the formation of FSGS lesions, interstitial fibrosis, proteinuria, glomerular hypertrophy, and accumulation of macrophages/monocytes as well as matrix proteins as indicated by FN mRNA and protein. This inhibitory effect on glomerular FN production and accumulation seems to be independent of the TGF-␤ system, since TGF-␤ mRNA and its typical target gene PAI-1 mRNA were unchanged by everolimus. Whether an inhibition of matrix accumulation or the reduction of accumulating inflammatory cells, such as macrophages/monocytes, are a primary or a secondary result of mTOR inhibition in this disease course is speculative. Nevertheless, this anti-inflammatory effect is important to notice, since even the proinflammatory actions of mTOR inhibitors have been described in response to certain cytokines in in vitro experiments [Saemann MD, personal commun.]. Consistent with our results in this study, a recent study demonstrated a direct inhibitory effect of macrophage adhesion via rapamycin-induced inhibition of rho-associated kinase-1 [31] causing reduced macrophage chemotaxis and phagocytosis. As shown before, everolimus reduced the number of glomerular cells positive for phosphorylated p70S6 kinase and decreased the amount of glomerular VEGF mRNA and protein. This is a reproducible result as shown by mTOR inhibitor treatment in many models of renal disease [8, [32] [33] [34] as well as in human renal (transplant) patients, and might be very important either for side effects or the positive effects of mTOR inhibition, dependent on the pathophysiological situation.
VEGF is the major pro-angiogenic factor that plays an important role in the development, maintenance, and repair of the endothelium in the kidney, as shown by the e55 elegant studies by Eremina et al. [35, 36] and others [37, 38] . To date, there is no other known cytokine which is equally tightly controlled within the glomerulus, and with which mice with glomerular selective deletion, haplo-insufficiency, isoform-specific deletion or overexpression of VEGF develop different but specific glomerular diseases [36] . Nevertheless, the consequences of VEGF alteration seem to depend on the specific requirements of the glomerulus. Since the everolimus-induced VEGF reduction in the chronic anti-Thy1 model, starting after the 2nd week of disease induction, did not lead to any severe alterations in the capillary convolute and architecture, but in the acute phase of the anti-Thy1 model with mesangiolytic, microaneurysmatic glomeruli, the same therapy was detrimental. It even cannot be excluded that VEGF reduction may be a causal part of this beneficial influence of everolimus on the time course of our disease model, when considering the adverse renal outcome in transgenic mice overexpressing VEGF in podocytes [36] or in transgenic rabbits overexpressing the human VEGF isoform in the kidney and liver [39] .
The beneficial effects of everolimus are consistent with the results in other published models of glomerular diseases, such as the aminonucleoside nephrosis model [9] , the mercuric chloride-induced glomerulopathy [40] or in experimental membranous nephropathy [41] . Where the glomerular architecture stays intact, no severe combined mesangial and endothelial (glomerular) lesion needs to be repaired. In contrast, everolimus therapy also worsened the time course of disease in a chronic model of low nephron number, the 5/6 nephrectomy model, in which both glomerular endothelial and mesangial injury were demonstrated [Vogelbacher R, et al., Transplantation, in press].
In conclusion, our results in a chronic mesangial proliferative glomerulonephritis model in the rat demonstrate that mTOR inhibition at clinically relevant drug levels (6-9 ng/ml) can be beneficial for the time course of disease by impairing proteinuria, the occurrence of FSGS lesions, interstitial fibrosis, glomerular hypertrophy, matrix accumulation and glomerular inflammation. This study further confirms our previous observation that the adverse effects of mTOR inhibition appear to be linked to severe combined glomerular lesions needing a timely repair of the capillary convolute.
